野村将药明合联(02268.HK) 2025年收入及盈利预测分别下调4.5%及8.7%,以反映公司上月公布的实际数据。展望2026年,预期收入将按年升37%至81亿元人民币(下同),大致符合市场预期,因考虑到更多项目进入临床试验申请后阶段,该部分的收入增长将加速。同时,该行预计来自商业化阶段项目的收入为1.81亿元,而收购东曜药业(01875.HK) 带来的收入则为1.5亿元。利润方面,该行料...
Source Link野村将药明合联(02268.HK) 2025年收入及盈利预测分别下调4.5%及8.7%,以反映公司上月公布的实际数据。展望2026年,预期收入将按年升37%至81亿元人民币(下同),大致符合市场预期,因考虑到更多项目进入临床试验申请后阶段,该部分的收入增长将加速。同时,该行预计来自商业化阶段项目的收入为1.81亿元,而收购东曜药业(01875.HK) 带来的收入则为1.5亿元。利润方面,该行料...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.